Inhibition of buthionine sulfoximine-enhanced doxorubicin toxicity in metallothionein overexpressing transgenic mouse heart

Journal of Pharmacology and Experimental Therapeutics

Volumn 287, Issue 2, 1998, Pages 515-520

  Wu, Hui Yun ^a   Kang, Y James ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; CREATINE KINASE; DOXORUBICIN; GLUTATHIONE; MALONALDEHYDE; METALLOTHIONEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; GENE OVEREXPRESSION; HEART PROTECTION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIDOTES; BUTHIONINE SULFOXIMINE; CREATINE KINASE; DOXORUBICIN; GLUTATHIONE; HEART; MALONDIALDEHYDE; METALLOTHIONEIN; MICE; MICE, TRANSGENIC; MYOCARDIUM;

EID: 0032463529     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Abel J and de Ruiter (1989) Inhibition of hydroxyl-radical-generated DNA degradation by metallothionein. Toxicol Lett 47:191-196.
2. Bachur NR, Gordon SL and Gee MW (1978) A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 38:1745-1750.
3. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alterti K, Tombes MB, Wilding G, Pomplun M and Spriggs DR (1994) Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 12:194-205.
4. Bull AW and Marnett LJ (1985) Determination of malondialdehyde by ion-pairing high-performance liquid chromatography. Anal Biochem 149:284-290.
5. Ceconi C, Cargnoni A, Pasini E, Cordorelli E, Curello S and Ferrari R (1992) Lipid peroxidation during myocardial reperfusion. Mol Cell Biochem 111:49-54.
6. DiSilvestro RA, Liu J and Klassen CD (1996) Transgenic mice overexpressing metallothionein are not resistant to adriamycin cardiotoxicity. Res Commun Mol Pathol Pharmacol 93:163-170.
7. Doroshow JH, Locker GY, Ifrim I and Myers CE (1981) Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest 68:1053-1064.
8. Dusre L, Mimnaugh EG, Myers CE and Sinha BK (1989) Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res 49:511-515.
9. Eaton KL and Cherian MG (1991) Determination of metallothionein in tissues by cadmium-hemoglobin affinity assay. Methods Enzymol 205:83-88.
10. Ebadi M, Leuschen MP, Refaey HE, Hamada FM and Rojas P (1996) The antioxidant properties of zinc and metallothionein. Neurochem Intl 29:159-166.
11. Esterbauer H, Long J, Zadravec S and Slater F (1984) Detection of malonaldehede by high-performance liquid chromatography. Methods Enzymol 105:319-328.
12. Esterbauer H and Zollner H (1989) Methods for determination of aldehydic lipid peroxidation products. Free Radical Biol Med 7:197-203.
13. Friedman HS, Colvin OM, Aisaka K, Popp J, Bossen EH, Reimer KA, Powell JB, Hilton J, Gross SS, Levi R, Bigner DD and Griffith OW (1990) Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res 50:2455-2462.
14. Griffith OW (1982) Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 257:13704-13712.
15. Hamer DH (1986) Metallothionein. Ann Rev Biochem 55:913-951.
16. Hatcher EL, Alexander JM and Kang YJ (1997) Decreased sensitivity to adriamycin in cadmium-resistant human lung carcinoma A549 cells. Biochem Pharmacol 53:747-754.
17. Iszard MB, Liu J, and Klassen CD (1995) Effect of several metallothionein inducers on oxidative stress defense mechanisms in rats. Toxicology 104:25-33.
18. Kalyanaraman B, Sealy RC and Sinha BK (1984) An electron spin resonance study of the reduction of peroxides by anthracycline semiquinones. Biochim Biophys Acta 779:270-275.
19. Kang YJ, Chen Y and Epstein PN (1996) Suppression of Doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem 271: 12610-12616.
20. Kang YJ, Chen Y, Yu AD, Voss-McCowan M and Epstein P (1997) Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 100:1501-1506.
21. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813-1815.
22. Kisara S, Furusawa S, Takayanagi Y and Sasaki K (1995) Effect of glutathione depletion by buthionine sulfoximine on doxorubicin toxicity in mice. Res Commun Mol Pathol Pharmacol 89:401-410.
23. Kojima S, Icho T, Hayashi M, Kakiwara Y, Kitabatake K and Kubota K (1993) Inhibitory effect of 5,6,7,8-tetrahydroneopterin on adriamycin-induced cardiotoxicity. J Pharmacol Exp Ther 266:1699-1704.
24. Kondo Y, Woo ES, Michalska AE, Choo KHA and Lazo JS (1995) Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res 55:2021-2023.
25. Loidl-Stahlhofen A and Spiteller G (1994) α-Hydroxyaldehydes, products of lipid peroxidation. Biochim Biophys Acta 1211:156-160.
26. Malayeri R, Filipits M, Suchomel RW, Zochbauer S, Lechuer K and Pirker R (1996) Multidrug resistance in leukemia and its reversal. Leukemia Lymphoma 23:451-458.
27. Naganuma A, Satoh M and Imura N (1988) Specific reduction of toxic side effects of adriamycin by induction of metallothionein in mice. Jpn J Cancer Res 79:406-411.
28. O'Dwyer PJ, Hamilton TC, Young RC, LaCreta FP, Carp N, Tew KD, Padavic K, Comis RL and Ozols RF (1992) Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst 84:264-267.
29. Oliver IT (1963) Improved method for determination of creatine kinase. J Lab Clin Med 62:159-164.
30. 2 with sulfhydryl groups in HL-60 cells: Zinc-metallothionein and other sites. Arch Biochem Biophys 334:241-250.
31. Russo A and Mitchell JB (1985) Potentiation and protection of doxorubicin cytotoxicity by cellular glutathione modulation. Cancer Treat Rep 69:1293-1296.
32. Sato M and Bremner (1993) Oxygen free radicals and metallothionein free radical biology and medicine. Free Radical Biol Med 14:325-337.
33. Satoh M, Naganuma A and Imura N (1988) Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination. Cancer Chemother Pharmacol 21:176-178.
34. Shen H, Kaurar L and Tew KD (1997) Importance of glutathione and associated enzymes in drug response. Oncology Res 9:295-302.
35. Thomas JP, Bachowski GL and Girotti AW (1986) Inhibition of cell membrane lipid peroxidation by cadmium-and zinc-metalothionein. Biochim Biophys Acta 884: 448-461.
36. Thornalley PJ and Vasak M (1985) Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals. Biochim Biophys Acta 827:36-44.
37. Tietze F (1969) Enzymic method of quantitative determination of amounts of total and oxidized glutathione: application to mammalian blood and other tissues. Anal Biochem 57:502-522.
38. Vallee BL (1995) The function of metallothionein. Neurochem Intl 27:23-33.
39. Villani F, Galimberti M, Monti E, Piccinini F, Lanza E, Rozza A, Favalli L, Poggi P and Zumino F (1990) Effect of GSH and N-acetylcysteine on in vitro and in vivo cardiac tosicity of doxurubicin. Free Rad Res Commun 11:145-151.
40. Yoda Y, Nakazawa M, Abe T and Kawakami Z (1986) Prevention of doxorubicin myocardial toxicity by reduced glutatione. Cancer Res 46:251-255.